Nevro (NYSE:NVRO) & Sensus Healthcare (NYSE:SRTS) Critical Survey
Nevro (NYSE:NVRO) and Sensus Healthcare (NASDAQ:SRTS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.
Earnings and Valuation
This table compares Nevro and Sensus Healthcare’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nevro||$387.29 million||6.57||-$49.21 million||($1.64)||-50.26|
|Sensus Healthcare||$26.43 million||3.83||-$2.02 million||($0.14)||-43.79|
This is a summary of recent recommendations for Nevro and Sensus Healthcare, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Nevro presently has a consensus target price of $62.50, suggesting a potential downside of 24.17%. Sensus Healthcare has a consensus target price of $9.50, suggesting a potential upside of 54.98%. Given Sensus Healthcare’s stronger consensus rating and higher probable upside, analysts plainly believe Sensus Healthcare is more favorable than Nevro.
This table compares Nevro and Sensus Healthcare’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
10.5% of Sensus Healthcare shares are owned by institutional investors. 7.6% of Nevro shares are owned by insiders. Comparatively, 31.2% of Sensus Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Nevro has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500.
Sensus Healthcare beats Nevro on 10 of the 13 factors compared between the two stocks.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
About Sensus Healthcare
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary robotic intraoperative radiation therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.